Head-to-head evidence
NNC0491-6075 vs Solbinsiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
NNC0491-6075
Developed by Novo Nordisk
NCT05979428 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported.
Solbinsiran
Developed by Eli Lilly
NCT05256654 · Phase 2 · completed
The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.
Next expected readout: March 2027 · NCT07269210 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0491-6075's landscape · Solbinsiran's landscape